A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
Completed · Phase 2 · NCT05358717
Conditions: Huntington Disease
At a glance
- Research payments reported, 2025
- $39,687
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 159
About the trial
- Sponsor
- Novartis Pharmaceuticals
- Tested
- PTC518 (drug), Placebo (drug)
- Dates
- Started 2022-06-03; completion 2025-07-31
- Results posted
- Yes
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
From ClinicalTrials.gov, last updated 2026-06-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ptc Therapeutics, Inc. reported $39,687 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Rajeev Kumar, MD Neurology · Englewood, CO
- Glenn Jaffe, M.D. Ophthalmology · Durham, NC
- Daniel O. Claassen, M.D. Neurology · Nashville, TN
- Erin E. Furr Stimming, M.D. Neurology · Houston, TX
- Suman Jayadev, MD Neurology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Duke University $11,568
- Vanderbilt University Medical Center, TN $8,761
- The University of Texas Health Science Center at Houston $6,494
- $5,900
- University of Washington Medical Ctr, WA $4,714
- Cenexel Rocky Mountain Clinical Research LLC $2,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.